Fresenius Medical Care AG (ETR:FME - Get Free Report) shares passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of €37.97 ($39.55) and traded as high as €44.56 ($46.42). Fresenius Medical Care shares last traded at €43.55 ($45.36), with a volume of 4,185,366 shares traded.
Fresenius Medical Care Stock Performance
The company has a fifty day moving average price of €41.19 and a two-hundred day moving average price of €38.00. The firm has a market cap of $12.78 billion, a price-to-earnings ratio of 24.06, a price-to-earnings-growth ratio of 0.42 and a beta of 0.86. The company has a debt-to-equity ratio of 77.56, a current ratio of 1.46 and a quick ratio of 0.80.
About Fresenius Medical Care
(
Get Free Report)
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Recommended Stories
Before you consider Fresenius Medical Care, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius Medical Care wasn't on the list.
While Fresenius Medical Care currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
